Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vertex Pharmaceuticals (NQ:VRTX)

520.88 +5.33 (+1.03%)
Streaming Delayed Price Updated: 10:16 AM EDT, Aug 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
76 77 Next >
News headline image
3 Cash-Producing Stocks on Our Watchlist
Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen ... 
Via StockStory
News headline image
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗
The drugmaker should significantly mitigate its most important risk as it develops new products. 
Via The Motley Fool
News headline image
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on an annualized basis producing an average annual return of 14.69%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
News headline image
Vertex (VRTX) Q2 2026 Earnings Call Transcript ↗
Revenue hit $3.3 billion with guidance raised on strong newer product growth. 
Via The Motley Fool
Topics Earnings
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation ↗
Via Chartmill
Discover which S&P500 stocks are making waves on Monday. ↗
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
Get insights into the top movers in the S&P500 index of Monday's pre-market session. ↗
Via Chartmill
News headline image
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call
Vertex Pharmaceuticals’ second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfol... 
Via StockStory
Topics Earnings
News headline image
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? ↗
This risk is weighing on the stock. 
Via The Motley Fool
News headline image
Why Vertex Pharmaceuticals Stock Ticked Higher on Tuesday ↗
The company notched a pair of modest beats in its second quarter. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Q2 Earnings Call Highlights ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising... 
Via MarketBeat
Topics Earnings
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. ... 
Via StockStory
News headline image
Vertex Reports Second Quarter 2026 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for. Vertex Pharmaceuticals be... 
Via StockStory
Topics Artificial Intelligence
News headline image
Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗
There are other reasons to pay attention to Viking Therapeutics. 
Via The Motley Fool
News headline image
Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗
The next six months may be decisive for the biotech. 
Via The Motley Fool
News headline image
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
From AbCellera Biologics Inc.
Via Business Wire
News headline image
3 Healthcare Stocks with Competitive Advantages
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching ↗
The biotech's diversification efforts continue. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ... 
Via StockStory
News headline image
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals... 
Via Benzinga
News headline image
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals ↗
Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be. 
Via The Motley Fool
News headline image
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? ↗
Vertex Pharmaceuticals recently announced its largest-ever acquisition. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a... 
Via MarketBeat
News headline image
Is This Biotech Stock a Buy Near Its 52-Week High? ↗
It's been a volatile year for the company, but don't let that scare you away. 
Via The Motley Fool
News headline image
Why This Pharmaceutical Stock Jumped Close to 100% This Week ↗
It is getting acquired by a larger firm in the sector. 
Via The Motley Fool
Topics Bonds
News headline image
3 Reasons to Buy CRISPR Therapeutics Stock ↗
The company's innovative qualities may pay rich dividends down the road. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
76 77 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.